keyword
MENU ▼
Read by QxMD icon Read
search

Locally advanced prostate cancer

keyword
https://www.readbyqxmd.com/read/28645325/performance-characteristics-of-prostate-specific-antigen-density-and-biopsy-core-details-to-predict-oncological-outcome-in-patients-with-intermediate-to-high-risk-prostate-cancer-underwent-robot-assisted-radical-prostatectomy
#1
Masahiro Yashi, Akinori Nukui, Yuumi Tokura, Kohei Takei, Issei Suzuki, Kazumasa Sakamoto, Hideo Yuki, Tsunehito Kambara, Hironori Betsunoh, Hideyuki Abe, Yoshitatsu Fukabori, Yoshimasa Nakazato, Yasushi Kaji, Takao Kamai
BACKGROUND: Many urologic surgeons refer to biopsy core details for decision making in cases of localized prostate cancer (PCa) to determine whether an extended resection and/or lymph node dissection should be performed. Furthermore, recent reports emphasize the predictive value of prostate-specific antigen density (PSAD) for further risk stratification, not only for low-risk PCa, but also for intermediate- and high-risk PCa. This study focused on these parameters and compared respective predictive impact on oncologic outcomes in Japanese PCa patients...
June 23, 2017: BMC Urology
https://www.readbyqxmd.com/read/28635336/new-advances-in-focal-therapy-for-early-stage-prostate-cancer
#2
Kae Jack Tay, Ariel A Schulman, Christina Sze, Efrat Tsivian, Thomas J Polascik
Prostate focal therapy offers men the opportunity to achieve oncological control while preserving sexual and urinary function. The prerequisites for successful focal therapy are to accurately identify, localize and completely ablate the clinically significant cancer(s) within the prostate. We aim to evaluate the evidence for current and upcoming technologies that could shape the future of prostate cancer focal therapy in the next five years. Areas Covered: Current literature on advances in patient selection using imaging, biopsy and biomarkers, ablation techniques and adjuvant treatments for focal therapy are summarized...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28635333/molecular-biomarkers-to-guide-precision-medicine-in-localized-prostate-cancer
#3
Minke Smits, Niven Mehra, Michiel Sedelaar, Winald Gerritsen, Jack A Schalken
Major advances through tumor profiling technologies, that include next-generation sequencing, epigenetic, proteomic and transcriptomic methods, have been made in primary prostate cancer, providing novel biomarkers that may guide precision medicine in the near future. Areas covered: The authors provided an overview of novel molecular biomarkers in tissue, blood and urine that may be used as clinical tools to assess prognosis, improve selection criteria for active surveillance programs, and detect disease relapse early in localized prostate cancer...
June 21, 2017: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/28632505/obesity-and-prostate-cancer
#4
Marco Bandini, Giorgio Gandaglia, Alberto Briganti
PURPOSE OF REVIEW: To investigate the association between obesity and prostate cancer (PCa). RECENT FINDINGS: Obesity has been proposed to be involved in the pathogenesis of PCa through different biological mechanisms that include deregulation of the insulin axis, sex hormone secretion, adipokines signaling, and oxidative stress. Hypertrophic peritumoral adipocytes may also facilitate the local spread of PCa through the chemo-attraction of tumor cells. Clinical studies demonstrate that obesity might have clinical implications also in disease detection and management...
June 16, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28631720/contemporary-management-of-men-with-high-risk-localized-prostate-cancer-in-the-united-states
#5
A B Weiner, R S Matulewicz, E M Schaeffer, S L Liauw, J M Feinglass, S E Eggener
BACKGROUND: Surgery and radiation-based therapies are standard management options for men with clinically localized high-risk prostate cancer (PCa). Contemporary patterns of care are unknown. We hypothesize the use of surgery has steadily increased in more recent years. METHODS: Using the National Cancer Data Base for 2004-2013, all men diagnosed with high-risk localized PCa were identified using National Comprehensive Cancer Network criteria. Temporal trends in initial management were assessed...
June 20, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28625691/a-case-of-locally-advanced-castration-resistant-prostate-cancer-with-remarkable-response-to-nivolumab
#6
Alina Basnet, Gaurav Khullar, Rohin Mehta, Namita Chittoria
No abstract text is available yet for this article.
May 24, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28618396/vitamin-d-receptor-binding-site-variants-affect-prostate-cancer-progression
#7
Victor C Lin, Shu-Pin Huang, Huei-Ju Ting, Wen-Lung Ma, Chia-Cheng Yu, Chao-Yuan Huang, Hsin-Ling Yin, Tsung-Yi Huang, Cheng-Hsueh Lee, Ta-Yuan Chang, Te-Ling Lu, Bo-Ying Bao
Vitamin D is an important modulator of cellular proliferation through the vitamin D receptor (VDR) that binds to DNA in the regulatory sequences of target genes. We hypothesized that single nucleotide polymorphisms (SNPs) in VDR-binding sites might affect target gene expression and influence the progression of prostate cancer. Using a genome-wide prediction database, 62 SNPs in VDR-binding sites were selected for genotyping in 515 prostate cancer patients and the findings were replicated in an independent cohort of 411 patients...
May 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28615267/the-novel-association-of-circulating-tumor-cells-and-circulating-megakaryocytes-with-prostate-cancer-prognosis
#8
Lei Xu, Xueying Mao, Tianyu Guo, Pui Ying Chan, Greg Shaw, John Hines, Elzbieta Stankiewicz, Yuqin Wang, R Tim D Oliver, Amar Sabri Ahmad, Daniel Berney, Jonathan Shamash, Yong-Jie Lu
To develop an approach for the investigation of different subtypes of circulating tumor cells (CTCs) and other cells to evaluate their potential prognostic value of prostate cancer.<br /><br />Experimental Design: Malignancy of CTCs undergoing epithelial to mesenchymal transition (EMT) was confirmed by repeated Fluorescence in situ hybridization. Subgroups of CTCs in 81 patients with prostate cancer (43 castration resistant and 38 untreated localized) were correlated to disease aggressiveness parameters...
June 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28608115/phase-i-trial-of-antigen-targeted-autologous-dendritic-cell-based-vaccine-with-in-vivo-activation-of-inducible-cd40-for-advanced-prostate-cancer
#9
Guru Sonpavde, John D McMannis, Yu Bai, Mamatha R Seethammagari, Joan M C Bull, Victoria Hawkins, Theresa K Dancsak, Natasha Lapteva, Jonathan M Levitt, Annemarie Moseley, David M Spencer, Kevin M Slawin
This phase I trial reports the safety and activity of BPX101, a second-generation antigen-targeted autologous antigen presenting cell (APC) vaccine in men with metastatic castration-resistant prostate cancer (mCRPC). To manufacture BPX101, APCs collected in a single leukapheresis were transduced with adenoviral vector Ad5f35 encoding inducible human (ih)-CD40, followed by incubation with protein PA001, which contains the extracellular domain of human prostate-specific membrane antigen. The ih-CD40 represents a modified chimeric version of the dendritic cell (DC) co-stimulatory molecule, CD40, which responds to a bioinert membrane-permeable activating dimerizer drug, rimiducid (AP1903), permitting temporally controlled, lymphoid-localized, DC-specific activation...
June 12, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28600675/a-novel-capillary-nano-immunoassay-for-assessing-androgen-receptor-splice-variant-7-in-plasma-correlation-with-cd133-antigen-expression-in-circulating-tumor-cells-a-pilot-study-in-prostate-cancer-patients
#10
J L García, R Lozano, I Misiewicz-Krzeminska, J Fernández-Mateos, P Krzeminski, S Alfonso, R A Marcos, R García, F Gómez-Veiga, Á Virseda, M Herrero, D Olmos, J J Cruz-Hernández
PURPOSE: Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients. METHODS: Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform...
June 9, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28599761/racial-disparity-in-localized-prostate-cancer-mortality
#11
Haichang Xin
This study aims to examine racial differences in all-cause mortality between African American (AA) and non-African American localized prostate cancer patients. This study advances academic discussion by being among the first to use a sample more representative of the general population that is different from certain subpopulations examined in literature. This study adopted a retrospective cohort study design using the Florida Cancer Data System. The hierarchical logistic regression was employed to analyze mortality in 2004 among living patients with localized prostate cancer from baseline 2000...
July 2017: Journal of the National Medical Association
https://www.readbyqxmd.com/read/28594087/adult-prostatic-sarcoma-a-contemporary-multicenter-rare-cancer-network-study
#12
Berardino De Bari, Bradley Stish, Mark Wayne Ball, Yacob Habboush, Paul Sargos, Marco Krengli, Alberto Bossi, Armando Stabile, Claudio Sole Pesutic, Laëtitia Lestrade, Robert Jan Smeenk, Barbara Alicja Jereczek-Fossa, Zilli Thomas, Gilles Créhange, Filippo Alongi, Nicholas Zaorsky, Mahmut Ozsahin
INTRODUCTION: Adult prostatic sarcoma (PS) is a rare disease. While surgery is considered the standard approach, the role of other therapies is not completely established. We report results of the largest multicentric contemporary cohort of PS patients. MATERIALS AND METHODS: This study included 61 adult PS patients treated in 16 American and European Institutions. Median age was 64.4 years (range: 22-87). Curative surgery was delivered in 48 patients (prostatectomy = 26, cystoprostatectomy = 22), usually with lymphadenectomy (n = 40)...
June 8, 2017: Prostate
https://www.readbyqxmd.com/read/28591719/stable-and-high-expression-of-galectin-8-tightly-controls-metastatic-progression-of-prostate-cancer
#13
Lucas Daniel Gentilini, Felipe Martín Jaworski, Carolina Tiraboschi, Ignacio González Pérez, Monica Lidia Kotler, Anne Chauchereau, Diego Jose Laderach, Daniel Compagno
Two decades ago, Galectin-8 was described as a prostate carcinoma biomarker since it is only expressed in the neoplastic prostate, but not in the healthy tissue. To date, no biological function has been attributed to Galectin-8 that could explain this differential expression. In this study we silenced Galectin-8 in two human prostate cancer cell lines, PC3 and IGR-CaP1, and designed a pre-clinical experimental model that allows monitoring the pathology from its early steps to the long-term metastatic stages...
May 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28589396/the-use-of-hormonal-therapy-to-augment-radiation-therapy-in-prostate-cancer-an-update
#14
REVIEW
Greg Kauffmann, Stanley L Liauw
PURPOSE OF REVIEW: Androgen deprivation therapy (ADT) is an important adjunctive therapy to external beam radiation therapy (RT) for the definitive management of prostate cancer. The role of ADT is well-established for locally advanced or high-risk disease in conjunction with standard doses of RT, but less defined for intermediate-risk disease or with dose-escalated RT. The goal of this review is to summarize evidence evaluating the combination of ADT/RT, focusing on recent trials and current controversies as they pertain to the practicing clinician...
July 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28588651/testosterone-suppression-with-a-unique-form-of-leuprorelin-acetate-as-a-solid-biodegradable-implant-in-patients-with-advanced-prostate-cancer-results-from-four-trials-and-comparison-with-the-traditional-leuprorelin-acetate-microspheres-formulation
#15
Mladen Solarić, Anders Bjartell, Ursula Thyroff-Friesinger, Davide Meani
BACKGROUND: There are two slow-release ready-to-use forms of leuprorelin acetate (1-month and 3-month) that are available as solid, biodegradable implants for the treatment of advanced, hormone-sensitive prostate cancer. These implants have been shown to be as effective as traditional leuprorelin acetate microspheres for achieving successful testosterone suppression (⩽0.5 ng/ml) and lowering prostate-specific antigen (PSA) levels. Here we further evaluate testosterone suppression levels from four clinical trials evaluating the 3-month leuprorelin implant, including analysis below the European Association of Urology (EAU) castration level (<0...
December 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28585779/the-impact-of-initial-cancer-stage-on-the-incidence-of-venous-thromboembolism-the-scandinavian-thrombosis-and-cancer-stac-cohort
#16
I L Gade, S K Braekkan, I A Naess, J-B Hansenx, S C Cannegieter, K Overvad, H Jensvoll, J Hammerstrøm, K Blix, A Tjønneland, S R Kristensen, M T Severinsen
BACKGROUND: Absolute measures of the impact of cancer stage on the incidence of venous thromboembolism (VTE) in distinct cancer types have not been investigated in a large population based cohort study. OBJECTIVES: To investigate differences in incidence rates of objectively confirmed VTE according to development of cancer in a large population based cohort study. Cancer type and stage at the time of diagnosis was taken into account. PATIENTS AND METHODS: The Scandinavian Thrombosis and Cancer cohort includes data regarding cancer types, stages and objectively confirmed VTE diagnoses among 144,952 participants followed from 1993 through 2012...
June 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28584509/prostate-cancer-detected-by-screening-in-a-semi-urban-community-in-southeast-nigeria-correlations-and-associations-between-anthropometric-measurements-and-prostate-specific-antigen
#17
Fred O Ugwumba, Agharighom D Okoh, Kevin N Echetabu, Emeka I Udeh, Ikenna I Nnabugwu
CONTEXT: Prostate cancer (PCa) is frequently diagnosed at advanced stages in Nigeria. AIMS: To determine the screen detected PCa prevalence in a suburban community and explore any relationships between prostate-specific antigen (PSA) and anthropometric measurements. SETTINGS AND DESIGN: Nsukka is a town and local government area (LGA) in Southeast Nigeria in Enugu State. Towns that share a common border with Nsukka are Edem Ani, Alor-uno, Opi, Orba, and Ede-Oballa...
January 2017: Nigerian Journal of Surgery: Official Publication of the Nigerian Surgical Research Society
https://www.readbyqxmd.com/read/28578639/abiraterone-for-prostate-cancer-not-previously-treated-with-hormone-therapy
#18
Nicholas D James, Johann S de Bono, Melissa R Spears, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Alastair W S Ritchie, Claire L Amos, Clare Gilson, Rob J Jones, David Matheson, Robin Millman, Gerhardt Attard, Simon Chowdhury, William R Cross, Silke Gillessen, Christopher C Parker, J Martin Russell, Dominik R Berthold, Chris Brawley, Fawzi Adab, San Aung, Alison J Birtle, Jo Bowen, Susannah Brock, Prabir Chakraborti, Catherine Ferguson, Joanna Gale, Emma Gray, Mohan Hingorani, Peter J Hoskin, Jason F Lester, Zafar I Malik, Fiona McKinna, Neil McPhail, Julian Money-Kyrle, Joe O'Sullivan, Omi Parikh, Andrew Protheroe, Angus Robinson, Narayanan N Srihari, Carys Thomas, John Wagstaff, James Wylie, Anjali Zarkar, Mahesh K B Parmar, Matthew R Sydes
Background Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design. Methods We randomly assigned patients in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily) (combination therapy). Local radiotherapy was mandated for patients with node-negative, nonmetastatic disease and encouraged for those with positive nodes...
June 3, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28567040/a-unique-cellular-and-molecular-microenvironment-is-present-in-tertiary-lymphoid-organs-of-patients-with-spontaneous-prostate-cancer-regression
#19
María de la Luz García-Hernández, Norma Ofelia Uribe-Uribe, Ricardo Espinosa-González, W Martin Kast, Shabaana A Khader, Javier Rangel-Moreno
OBJECTIVE: Multiple solid cancers contain tertiary lymphoid organs (TLO). However, it is unclear whether they promote tumor rejection, facilitate tumor evasion, or simply whether they are a byproduct of chronic inflammation. We hypothesize that although chronic inflammation induces TLO formation, the tumor milieu can modulate TLO organization and functions in prostate cancer. Therefore, our study seeks to elucidate the cellular and molecular signatures in unique prostatectomy specimens from evanescent carcinoma patients to identify markers of cancer regression, which could be harnessed to modulate local immunosuppression or potentially enhance TLO function...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28560677/mesenchymal-epithelial-transition-and-circulating-tumor-cells-in-small-cell-lung-cancer
#20
Gerhard Hamilton, Barbara Rath
Cancer patients die of metastatic disease but knowledge regarding individual steps of this complex process of intravasation, spread and extravasation leading to secondary lesions is incomplete. Subpopulations of tumor cells are supposed to undergo an epithelial-mesenchymal transition (EMT), to enter the bloodstream and eventually establish metastases in a reverse process termed mesenchymal-epithelial transition (MET). Small cell lung cancer (SCLC) represents a unique model to study metastatic spread due to early dissemination and relapse, as well as availability of a panel of circulating cancer cell (CTC) lines recently...
2017: Advances in Experimental Medicine and Biology
keyword
keyword
3465
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"